DK2842945T3 - Sulfonamid-derivat og medicinsk anvendelse deraf - Google Patents

Sulfonamid-derivat og medicinsk anvendelse deraf Download PDF

Info

Publication number
DK2842945T3
DK2842945T3 DK13781307.7T DK13781307T DK2842945T3 DK 2842945 T3 DK2842945 T3 DK 2842945T3 DK 13781307 T DK13781307 T DK 13781307T DK 2842945 T3 DK2842945 T3 DK 2842945T3
Authority
DK
Denmark
Prior art keywords
group
groups
mmol
followed
methyl
Prior art date
Application number
DK13781307.7T
Other languages
English (en)
Inventor
Hirokazu Ueno
Takashi Yamamoto
Ryuta Takashita
Ryohei Yokoyama
Toshihiko Sugiura
Shunsuke Kageyama
Ayatoshi Ando
Hiroyuki Eda
Agung Eviryanti
Tomoko Miyazawa
Aya KIRIHARA
Itsuya Tanabe
Tarou Nakamura
Misato Noguchi
Manami SHUTO
Masayuki Sugiki
Mizuki DOHI
Original Assignee
Ea Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ea Pharma Co Ltd filed Critical Ea Pharma Co Ltd
Application granted granted Critical
Publication of DK2842945T3 publication Critical patent/DK2842945T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (19)

1. Sulfonamid-derivat med den følgende almene formel (1) eller et farmaceutisk acceptabelt salt deraf:
(i), hvor A betegner en gruppe med den følgende almene formel (2-1), (2-2) eller (2- 3),
( 2 - 1 ) ( 2 - 2 )
(2-3) , hvor Arm er en cyklisk alkylgruppe eller aromatisk ring indeholdende 0, 1, 2, 3 eller 4 heteroatomer udvalgt blandt oxygenatomer, svovlatomer og nitrogenatomer, R1, R11 og R21 hver især uafhængigt betegner en hvilken som helst af et hydrogenatom, et halogenatom, en hydroxylgruppe, en lavere alkylgruppe, en lavere alkenylgruppe, en lavere alkynylgruppe, en lavere alkoxygruppe, en lavere alkylthiogruppe, en lavere hydroxyalkylgruppe, en lavere hydroxy-alkenylgruppe, en lavere hydroxyalkoxygruppe, en lavere halogenoalkyl-gruppe, en lavere halogenoalkoxygruppe, en lavere halogenoalkylthiogruppe, en lavere halogenoalkenylgruppe, en nitrogruppe, en cyanogruppe, en ami-nogruppe, en lavere alkylaminogruppe, en (lavere alkylamino)lavere alkylgruppe, en carboxylgruppe, en lavere alkyloxycarbonylgruppe, en carbamoyl-gruppe, en lavere alkanoylgruppe, an aroylgruppe, en lavere alkylsulfonyl-gruppe, en sulfamoylgruppe og en ammoniumgruppe, R12, R13 og R14 hver især uafhængigt betegner en hvilken som helst af et hydrogenatom, et halogenatom, en hydroxylgruppe, en lavere alkylgruppe, en lavere alkenylgruppe, en lavere alkynylgruppe, en lavere alkoxygruppe, en lavere alkylthiogruppe, en lavere hydroxyalkylgruppe, en lavere hydroxy-alkenylgruppe, en lavere hydroxyalkoxygruppe, en lavere halogenoalkyl-gruppe, en lavere halogenoalkoxygruppe, en lavere halogenoalkylthiogruppe, en lavere halogenoalkenylgruppe, en nitrogruppe, en cyanogruppe, an ami-nogruppe, en lavere alkylaminogruppe, en (lavere alkylamino)lavere alkylgruppe, en carboxylgruppe, en lavere alkyloxycarbonylgruppe, a carbamoyl-gruppe, en lavere alkanoylgruppe, an aroylgruppe, en lavere alkylsulfonyl-gruppe, en sulfamoylgruppe og en ammoniumgruppe, R2, R3, R22, R23, R24 og R25 hver især uafhængigt betegner en hvilken som helst af et hydrogenatom, et halogenatom, en hydroxylgruppe, en lavere alkylgruppe, en lavere alkenylgruppe, en lavere alkynylgruppe, en lavere alkoxygruppe, en lavere alkylthiogruppe, en lavere hydroxyalkylgruppe, en lavere hydroxyalkenylgruppe, en lavere hydroxyalkoxygruppe, en lavere halogenoalkylgruppe, en lavere halogenoalkoxygruppe, en lavere halogenoalkylthiogruppe, en lavere halogenoalkenylgruppe, en nitrogruppe, en cyanogruppe, en aminogruppe, en lavere alkylaminogruppe, en (lavere alkylami-no)lavere alkylgruppe, en carboxylgruppe, en lavere alkyloxycarbonylgruppe, en carbamoylgruppe, en lavere alkanoylgruppe, en aroylgruppe, en lavere alkylsulfonylgruppe, en sulfamoylgruppe og en ammoniumgruppe, B betegner en hvilken som helst af en hydroxylgruppe, en hydroxyamino-gruppe, en cycloheptyloxygruppe, eller en lavere alkoxygruppe eventuelt substitueret med en arylgruppe(r), en hydroxylgruppe(r), en lavere alkylgruppe(r), en lavere alkylaminogrup-pe(r), og/eller en heterocyklisk gruppe(r), R41 betegner et hydrogenatom eller en lavere alkylgruppe, a, b, c og d hver især uafhængigt betegner C-R31, C-R32, C-R33 og C-R34, respektivt, men en eller to af a, b, c og d hver især kan betegne et nitrogenatom, R31, R32, R33 og R34 hver især uafhængigt betegner en hvilken som helst af et hydrogenatom, et halogenatom, en lavere alkylgruppe, en lavere alkoxygruppe og en nitrogruppe, forudsat at en hvilken som helst af R31, R32, R33 og R34 er et halogenatom eller en lavere alkylgruppe, e, f, g og h hver især uafhængigt betegner C-R35, C-R36, C-R37 og C-R38, respektivt, men en eller to af e, f, g og h hver især kan betegne et nitrogenatom, R35, R36, R37 og R38 hver især uafhængigt er et hvilket som helst af et hydrogenatom, et halogenatom, en lavere alkylgruppe, en lavere alkoxygruppe og en nitrogruppe, D betegner en phenylgruppe eller heterocyklisk gruppe eventuelt med en substituent(er) udvalgt fra gruppen bestående af halogenatomer, hydroxyl-grupper, lavere alkylgrupper, lavere alkenylgrupper, lavere alkynylgrupper, lavere alkoxygrupper, lavere alkylthiogrupper, lavere hydroxyalkylgrupper, lavere hydroxyalkenylgrupper, lavere hydroxyalkoxygrupper, lavere halogen-oalkylgrupper, lavere halogenoalkoxygrupper, lavere halogenoalkylthiogrup-per, lavere halogenoalkenylgrupper, nitrogrupper, cyanogrupper, aminogrup-per, carboxylgrupper, lavere alkyloxycarbonylgrupper, carbamoylgrupper, lavere alkanoylgrupper, aroylgrupper, lavere alkylsulfonylgrupper, sulfamoyl-grupper og ammoniumgrupper og E betegner en 5- eller 6-leddet heterocyklisk gruppe eventuelt med en sub-stituent(er) udvalgt fra gruppen bestående af halogenatomer, hydroxylgrup-per, lavere alkylgrupper, lavere alkenylgrupper, lavere alkynylgrupper, lavere alkoxygrupper, lavere alkylthiogrupper, lavere hydroxyalkylgrupper, lavere hydroxyalkenylgrupper, lavere hydroxyalkoxygrupper, lavere halogenoalkyl-grupper, lavere halogenoalkoxygrupper, lavere halogenoalkylthiogrupper, lavere halogenoalkenylgrupper, nitrogrupper, cyanogrupper, aminogrupper, 4- til 6-leddet cykliske aminogrupper, carboxylgrupper, lavere alkyloxycarbo-nylgrupper, carbamoylgrupper, lavere alkanoylgrupper, aroylgrupper, lavere alkylsulfonylgrupper, sulfamoylgrupper og ammoniumgrupper; en aminocar-bonylgruppe eventuelt med en substituent(er) udvalgt fra gruppen bestående af hydroxylgrupper, lavere alkylgrupper, lavere alkenylgrupper, lavere alky-nylgrupper, lavere alkoxygrupper, lavere hydroxyalkylgrupper, lavere hydroxyalkenylgrupper, lavere hydroxyalkoxygrupper, lavere halogenoalkylgrup-per, lavere halogenoalkoxygrupper, lavere halogenoalkenylgrupper, aminogrupper, lavere alkylaminogrupper, arylgrupper, heterocykliske grupper, het-erocyklus-substituerede lavere alkylgrupper, lavere alkylsulfonylgrupper og sulfamoylgrupper; et hydrogenatom, et halogenatom, en hydroxylgruppe, en lavere alkylgruppe, en lavere alkenylgruppe, en lavere alkynylgruppe, en lavere alkoxygruppe, en lavere alkylthiogruppe, en lavere hydroxyalkylgruppe, en lavere hydroxyalkenylgruppe, en lavere hydroxyalkoxygruppe, en lavere halogenoalkylgruppe, en lavere halogenoalkoxygruppe, en lavere halogen-oalkylthiogruppe, en lavere halogenoalkenylgruppe, en nitrogruppe, en cy-anogruppe, en aminogruppe, en carboxylgruppe, en dihydroxyborylgruppe, en lavere alkylcarbonylgruppe, en lavere alkyloxycarbonylgruppe, en car-bamoylgruppe, en lavere alkanoylgruppe, en aroylgruppe, en lavere alkyl-sulfonylgruppe, en sulfamoylgruppe, en ammoniumgruppe eller en lavere alkylaminoalkylenegruppe, forudsat at den lavere alkylcarbonylgruppe og den lavere alkyloxycarbonylgruppe hver især kan være bundet til phenylgruppen repræsenteret af D for at danne en kondenseret ring; og hvor termen "lavere" betyder, at den således betegnede funktionelle gruppe omfatter fra 1 til 6 carbonatomer.
2. Sulfonamid-derivat ifølge krav 1 eller et farmaceutisk acceptabelt salt deraf, hvor E betegner en 5- eller 6-leddet heterocyklisk gruppe eventuelt med en sub-stituent(er) udvalgt fra gruppen bestående af halogenatomer, hydroxylgrupper, lavere alkylgrupper, lavere alkenylgrupper, lavere alkynylgrupper, lavere alkoxygrupper, lavere alkylthiogrupper, lavere hydroxyalkylgrupper, lavere hydroxyalkenylgrupper, lavere hydroxyalkoxygrupper, lavere halogenoalkyl-grupper, lavere halogenoalkoxygrupper, lavere halogenoalkylthiogrupper, lavere halogenoalkenylgrupper, nitrogrupper, cyanogrupper, aminogrupper, carboxylgrupper, lavere alkyloxycarbonylgrupper, carbamoylgrupper, lavere alkanoylgrupper, aroylgrupper, lavere alkylsulfonylgrupper, sulfamoylgrupper og ammoniumgrupper; en aminocarbonylgruppe eventuelt med en substitu-ent(er) udvalgt fra gruppen bestående af hydroxylgrupper, lavere alkylgrup-per, lavere alkenylgrupper, lavere alkynylgrupper, lavere alkoxygrupper, lavere hydroxyalkylgrupper, lavere hydroxyalkenylgrupper, lavere hydroxyalkoxygrupper, lavere halogenoalkylgrupper, lavere halogenoalkoxygrupper, lavere halogenoalkenylgrupper, aminogrupper, lavere alkylaminogrupper, arylgrupper, heterocykliske grupper, lavere alkylsulfonylgrupper og sulfamoylgrupper; et hydrogenatom, et halogenatom, en hydroxylgruppe, en lavere alkylgruppe, en lavere alkenylgruppe, en lavere alkynylgruppe, en lavere alkoxygruppe, en lavere alkylthiogruppe, en lavere hydroxyalkyl-gruppe, en lavere hydroxyalkenylgruppe, en lavere hydroxyalkoxygruppe, en lavere halogenoalkylgruppe, en lavere halogenoalkoxygruppe, en lavere halogenoalkylthiogruppe, en lavere halogenoalkenylgruppe, en nitrogruppe, en cyanogruppe, en aminogruppe, en carboxylgruppe, en dihydroxyboryl-gruppe, en lavere alkyloxycarbonylgruppe, en carbamoylgruppe, en lavere alkanoylgruppe, en aroylgruppe, en lavere alkylsulfonylgruppe, en sulfamoyl-gruppe, en ammoniumgruppe eller en lavere alkylaminoalkylengruppe.
3. Sulfonamid-derivat ifølge krav 1 eller et farmaceutisk acceptabelt salt deraf, hvor D er en phenylgruppe eventuelt med en substituent(er) udvalgt fra gruppen bestående af lavere alkylgrupper, halogenatomer, hydroxylgrupper og lavere alkoxygrupper.
4. Sulfonamid-derivat ifølge krav 1 eller et farmaceutisk acceptabelt salt deraf, hvor D er en 6-leddet aromatisk heterocyklisk gruppe indeholdende et nitrogen-atom(er) som et ring-konstituentatom(er) og eventuelt med en substituent(er) udvalgt fra gruppen bestående af lavere alkylgrupper, halogenatomer og lavere alkoxygrupper.
5. Sulfonamid-derivat ifølge krav 4 eller et farmaceutisk acceptabelt salt deraf, hvor den heterocykliske gruppe repræsenteret af D er en pyridylgruppe eller pyr-rolgruppe eventuelt med en substituent(er) udvalgt fra gruppen bestående af lavere alkylgrupper, halogenatomer og lavere alkoxygrupper.
6. Sulfonamid-derivat ifølge et af kravene 1 til 5 eller et farmaceutisk acceptabelt salt deraf, hvor E er en 5- eller 6-leddet aromatisk heterocyklisk gruppe indeholdende 1,2, 3, eller 4 heteroatomer udvalgt blandt oxygenatomer, svovlatomer og nitrogenatomer and eventuelt med en substituent(er) udvalgt fra gruppen bestående af lavere alkylgrupper, lavere alkoxygrupper og halogenatomer.
7. Sulfonamid-derivat ifølge krav 6 eller et farmaceutisk acceptabelt salt deraf, hvor den aromatiske heterocykliske gruppe er udvalgt fra gruppen bestående af en pyridylgruppe, en pyridazylgruppe, en pyrimidylgruppe, en pyrazinylgrup-pe, en pyrrolylgruppe, en furanylgruppe, en thiophenylgruppe, en thiazolyl-gruppe, en oxazolylgruppe, en triazolylgruppe og en tetrazolgruppe.
8. Sulfonamid-derivat ifølge et af kravene 1 til 4 eller et farmaceutisk acceptabelt salt deraf, hvor E er en aminocarbonylgruppe eller lavere alkylaminoalkylengruppe eventuelt substitueret med en lavere alkylgruppe(r), en heterocyklisk gruppe(r) og/eller en heterocyklus-substitueret lavere alkylgruppe(r).
9. Sulfonamid-derivat ifølge et af kravene 1 til 6 og 8 eller et farmaceutisk acceptabelt salt deraf, hvor hver lavere alkylgruppe er en ligekædet, forgrenet eller cyklisk alkylgruppe.
10. Sulfonamid-derivat ifølge et af kravene 1 til 9 eller et farmaceutisk acceptabelt salt deraf, hvor R1, R11 og R21 er lavere alkylgrupper.
11. Sulfonamid-derivat ifølge et af kravene 1 til 10 eller et farmaceutisk acceptabelt salt deraf, hvor Arm er udvalgt fra gruppen bestående af en phenylgruppe, en pyridylgruppe og en imidazolylgruppe.
12. Sulfonamid-derivat ifølge et af kravene 1 til 11 eller et farmaceutisk acceptabelt salt deraf, hvor en af R31, R32, R33 og R34 er et halogenatom og resten er hydrogenatomer, eller to af R31, R32, R33 og R34 er halogenatomer og resten er hydrogenatomer.
13. Sulfonamid-derivat ifølge krav 1 eller et farmaceutisk acceptabelt salt deraf, hvor A er en gruppe med den almene formel (2-1) eller (2-2), i hvilken Arm er en pyridylgruppe eller en imidazolylgruppe og R1 og R11 er lavere alkylgrupper, to af R31, R32, R33 og R34 er halogenatomer og resten er hydrogenatomer, g er et carbon- eller nitrogenatom, e er et carbon- eller nitrogenatom, D er en phenylgruppe eventuelt med et halogenatom(er), en lavere alkyl-gruppe(r) og/eller en lavere alkoxygruppe(r), en furylgruppe(r) eller en pyridylgruppe eventuelt med et halogenatom(r), en lavere alkylgruppe(r), og/eller en lavere alkoxygruppe(r), og E er en pyridylgruppe, pyrimidylgruppe, triazolylgruppe eller pyrrolylgruppe eventuelt med en lavere alkylgruppe(r) og/eller en 4- til 6-leddet cyklisk ami-nogruppe(r), eller en aminocarbonylgruppe eventuelt substitueret med en lavere alkyl eller heterocyklus-substitueret lavere alkylgruppe(r).
14. Sulfonamid-derivat ifølge krav 1 med en af de følgende formler eller et farmaceutisk acceptabelt salt deraf:
15. Sulfonamid-derivat med en af de følgende formler eller et farmaceutisk acceptabelt salt deraf
16. Farmaceutisk sammensætning omfattende sulfonamid-derivatet ifølge et af kravene 1 til 15 eller et farmaceutisk acceptabelt salt deraf.
17. Middel til anvendelse ved behandling eller forebyggelse af en inflammatorisk sygdom, hvor en a4p7-integrin-afhængig adhæsionsproces er associeret med en patologisk tilstand, hvor midlet omfatter, som en aktiv bestanddel, sulfonamid-derivatet ifølge et af kravene 1 til 15 eller et farmaceutisk acceptabelt salt deraf.
18. Sulfonamid-derivat ifølge et af kravene 1 til 15, eller et farmaceutisk acceptabelt salt deraf, til anvendelse ved behandling eller forebyggelse af en hvilken som helst af inflammatoriske sygdomme, rheumatoid arthritis, inflammatorisktarmsygdom, systemisk lupus erythematosus, multipel sklerose, Sjogrens syndrom, asthma, psoriasis, allergi, diabetes mellitus, kardiovasku-lære sygdomme, arteriosklerose, restenose, tumorvækst, tumormetastase og transplantatafstødelse, hvor en a4-integrin-afhængig adhæsionsprocess er associeret med en patologisk tilstand.
19. Sulfonamid-derivat ifølge et af kravene 1 til 15 eller et farmaceutisk acceptabelt salt deraf til anvendelse som en a4p7-integrin-inhibitor.
DK13781307.7T 2012-04-24 2013-04-24 Sulfonamid-derivat og medicinsk anvendelse deraf DK2842945T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012098562 2012-04-24
JP2013054270 2013-03-15
PCT/JP2013/062121 WO2013161904A1 (ja) 2012-04-24 2013-04-24 スルホンアミド誘導体及びその医薬用途

Publications (1)

Publication Number Publication Date
DK2842945T3 true DK2842945T3 (da) 2017-01-30

Family

ID=49483212

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13781307.7T DK2842945T3 (da) 2012-04-24 2013-04-24 Sulfonamid-derivat og medicinsk anvendelse deraf

Country Status (13)

Country Link
US (1) US9533985B2 (da)
EP (1) EP2842945B1 (da)
JP (1) JP6152093B2 (da)
KR (1) KR101698796B1 (da)
CN (1) CN104395297B (da)
BR (1) BR112014026409B1 (da)
CA (1) CA2871464C (da)
DK (1) DK2842945T3 (da)
ES (1) ES2609524T3 (da)
MX (1) MX351225B (da)
PL (1) PL2842945T3 (da)
RU (1) RU2607081C2 (da)
WO (1) WO2013161904A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016005528A (es) * 2013-10-29 2016-10-03 Ea Pharma Co Ltd Derivado de sulfonamida y uso farmaceutico del mismo.
WO2015115507A1 (ja) * 2014-01-28 2015-08-06 味の素株式会社 複素環スルホンアミド誘導体及びそれを含有する医薬
EP3256461B1 (en) 2015-02-13 2023-09-13 Azienda Ospedaliera Universitaria Senese Urea and sulfonamide derivatives as human helicase ddx3 inhibitors useful in the treatment of viral diseases
TW201731824A (zh) * 2016-02-05 2017-09-16 Ea Pharma Co Ltd α４β７整合蛋白抑制劑
CN108699008B (zh) * 2016-02-05 2021-10-08 Ea制药株式会社 磺酰胺衍生物和含有其的药物组合物
US11111273B2 (en) * 2016-11-11 2021-09-07 Zealand Pharma A/S Cyclic peptides multimers targeting alpha-4-beta-7 integrin
CN110891964A (zh) 2017-05-10 2020-03-17 循环治疗学公司 靶向α4β7整合素的均环肽
CN111971283B (zh) * 2018-03-26 2023-04-14 肿瘤研究所基金会 具有增强的抗肿瘤作用的新型化合物
CN108752312A (zh) * 2018-08-29 2018-11-06 常州沃腾化工科技有限公司 一种新的制备2-甲基-3-噻吩-5-甲氧羰基磺酰氯的方法
WO2020092383A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
WO2020092394A1 (en) * 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CA3116769C (en) 2018-10-30 2023-08-22 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
WO2020094363A1 (en) 2018-11-05 2020-05-14 Syngenta Participations Ag Pesticidally active azole-amide compounds
JP2022525809A (ja) 2019-03-22 2022-05-19 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺虫剤としてのｎ－［１－（５－ブロモ－２－ピリミジン－２－イル－１，２，４－トリアゾール－３－イル）エチル］－２－シクロプロピル－６－（トリフルオロメチル）ピリジン－４－カルボキサミド誘導体及び関連化合物
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CN112830893A (zh) * 2019-10-28 2021-05-25 成都倍特药业股份有限公司 一类RORγ抑制剂、其制备方法及其在医药上的应用
CN111574414A (zh) * 2020-05-20 2020-08-25 上海毕得医药科技有限公司 一种4-溴-2-甲氧基苯磺酰氯的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016329A1 (fr) 2000-08-18 2002-02-28 Ajinomoto Co., Inc. Nouveaux derives de phenylalanine
EP1454898A4 (en) * 2001-12-13 2006-12-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
EP1477482B1 (en) * 2002-02-20 2010-04-14 Ajinomoto Co., Inc. Novel phenylalanine derivative
JPWO2003089410A1 (ja) * 2002-04-19 2005-08-25 協和醗酵工業株式会社 フェニルアラニン誘導体
CN1898213A (zh) * 2003-12-19 2007-01-17 巴斯福股份公司 具有除草作用的杂芳酰基取代的苯基丙氨酸酰胺
WO2005061466A1 (ja) * 2003-12-22 2005-07-07 Ajinomoto Co., Inc. 新規フェニルアラニン誘導体
KR20070012408A (ko) 2004-04-16 2007-01-25 제넨테크, 인크. Ｂ 세포 고갈을 증대시키는 방법
JP5273587B2 (ja) 2006-11-22 2013-08-28 味の素株式会社 キナゾリンジオン骨格を有するフェニルアラニン誘導体の製造方法及び製造中間体
WO2008064823A1 (en) 2006-11-27 2008-06-05 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
EP2993173A1 (en) * 2010-03-29 2016-03-09 Ajinomoto Co., Inc. Crystals of salts of phenylalanine derivatives

Also Published As

Publication number Publication date
US20150051395A1 (en) 2015-02-19
RU2014146995A (ru) 2016-06-10
BR112014026409A2 (pt) 2018-09-18
MX351225B (es) 2017-10-05
CA2871464A1 (en) 2013-10-31
WO2013161904A1 (ja) 2013-10-31
BR112014026409B1 (pt) 2022-09-06
KR101698796B1 (ko) 2017-01-23
CN104395297A (zh) 2015-03-04
PL2842945T3 (pl) 2017-04-28
MX2014012814A (es) 2015-05-08
RU2607081C2 (ru) 2017-01-10
ES2609524T3 (es) 2017-04-20
CA2871464C (en) 2017-09-26
JP6152093B2 (ja) 2017-06-21
EP2842945A4 (en) 2015-09-16
KR20150009558A (ko) 2015-01-26
US9533985B2 (en) 2017-01-03
JPWO2013161904A1 (ja) 2015-12-24
EP2842945A1 (en) 2015-03-04
EP2842945B1 (en) 2016-10-26
CN104395297B (zh) 2016-05-04

Similar Documents

Publication Publication Date Title
DK2842945T3 (da) Sulfonamid-derivat og medicinsk anvendelse deraf
AU2018222943B2 (en) Heterocyclic compounds useful as PDK1 inhibitors
AU2014240388B2 (en) Substituted 7-azabicycles and their use as orexin receptor modulators
JP6422878B2 (ja) スルホンアミド誘導体及びその医薬用途
AU2014248763A1 (en) Substituted piperidine compounds and their use as orexin receptor modulators
WO2018079628A1 (ja) 縮環ピロール誘導体およびその医薬用途